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Fanconi Anemia (FA) is a genetic disorder characterized by the inability of patient cells to repair DNA damage caused by
interstrand crosslinking agents. There are currently 14 verified FA genes, where mutation of any single gene prevents repair of
DNA interstrand crosslinks (ICLs). The accumulation of ICL damage results in genome instability and patients having a high
predisposition to cancers. The key event of the FA pathway is dependent on an eight-protein core complex (CC), required for the
monoubiquitination of each member of the FANCD2-FANCI complex. Interestingly, the majority of patient mutations reside in
the CC. The molecular mechanisms underlying the requirement for such a large complex to carry out a monoubiquitination event
remain a mystery. This paper documents the extensive eﬀorts of researchers so far to understand the molecular roles of the CC
proteins with regard to its main function in the FA pathway, the monoubiquitination of FANCD2 and FANCI.
1. Introduction
Fanconi Anemia (FA) patients present a variety of symptoms
including skeletal and developmental defects, bone marrow
failure, and a high predisposition to cancer [1]. The pre-
disposition to cancer is attributed to the FA pathway being
involved in DNA damage repair, particularly interstrand
crosslinks (ICLs). FA patients are highly susceptible to
crosslinking agents such as mitomycin C (MMC) and cis-
platin. Such treatment results in chromosome abnormalities,
and sensitivity to these agents is used as a diagnostic tool
for FA [2]. Currently there are 14 verified FA genes [3–22],
with a possible additional gene FANCO/Rad51C [23, 24],
that make up the FA pathway. Mutations in any of the 15
genes results in the loss of ICL repair. The key event of the FA
pathway is the monoubiquitination of FANCD2 and FANCI
[4–7], which triggers the downstream factors, FANCP/SLX4,
FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2 [9, 10,
17–22] to repair DNA damage (Figure 1). Only one protein
to date has been shown to have E3 ubiquitin ligase activity,
FANCL [8]. FANCL is a member of the Fanconi Anemia
Core Complex (CC), consisting of 7 other FA proteins:
FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and
FANCM (Figure 1) [3, 25–28]. Additionally, there are the
Fanconi Anemia Associated Proteins (FAAPs), which are
not yet found mutated in patients but form part of the
CC: FAAP100, FAAP24, and most recently FAAP20 [29–33].
MHF1 and MHF2 (also known as FAAP16 and FAAP10)
have also been implicated in the FA pathway through their
association with FANCM [34, 35]. Approximately 90% of
patient mutations reside in the CC, most of which are
found in FANCA (60%) (Table 1) [36]. Importantly a single
mutation in any of the 8 genes that make up the CC prevents
the key monoubiquitination event from occurring. Extensive
research eﬀorts have been made to understand the role
of the individual CC proteins and the requirement of all
CC proteins for the monoubiquitination event. This paper
outlines our current understanding of the molecular interac-
tions within the core complex and highlights key remaining
questions for a full molecular understanding of the CC.
2. E3 Ligase Function of the CC
Patient mutations in any member of a CC protein result
in the loss of the critical monoubiquitination of the
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Figure 1: The Fanconi Anemia Pathway. A model of the Fanconi Anemia Pathway at a stalled DNA (grey) replication fork, caused by an
interstrand crosslink (ICL). FANCM and its associated genes are coloured green, which assemble on DNA at the stalled replication fork. The
other CC proteins are represented by blue with FANCL as the E3 ligase of the CC represented by mauve. The substrates for ubiquitination
FANCD2 and FANCI are coloured gold and peach, respectively, with their associated ubiquitins represented by purple stars. The DNA repair
machinery is coloured pink.
FANCI/FANCD2 complex. All CC proteins appear to be
required for this event in vivo; therefore, historically the CC
has been regarded as a multisubunit E3 ligase. Multisubunit
E3 ligases such as the Cullin-RING ligases (CRLs) and the
Anaphase Promoting Complex (APC) are well understood
at the molecular level, with their modularity essential for
function.
The CRLs consist of a Cullin scaﬀold protein, which
associates with either Rbx1 or Rbx2 RING proteins, the
subunit responsible for binding the E2 carrying the activated
ubiquitin moiety [37]. The Cullin and RING therefore form
the catalytic unit of the CRL. In order for a substrate
to become ubiquitinated, it must be recognised by the
CRL. This is achieved by the substrate receptor proteins,
which associate through an adaptor protein onto the Cullin
scaﬀold, forming the complete CRL (Figure 2(a)) [37]. A
plethora of diﬀerent substrate recognition proteins for a
single Cullin achieves flexibility within the CRLs to target a
repertoire of substrates.
The APC also targets a variety of substrates to control
cell cycle progression from metaphase to anaphase. Similarly
to the CRLs the APC comprises of a Cullin repeat protein
Apc2, which binds the RING protein Apc11, and also Apc10
involved in substrate association. Together, these 3 subunits
form the catalytic unit. However, in contrast to CRLs the
APC contains an additional 10 proteins (Figure 2(b)). Apc9
and 13 and Cdc26 are structural stabilizers, whereas Apc1,
4, and 5 form a scaﬀold platform for the catalytic unit
[38]. The scaﬀold platform along with the tetratricopeptide
repeat (TPR) proteins Cdc23, Cdc27, Cdc16, and structural
stabilizer Cdc26 forms the TPR subcomplex, orientating the
catalytic unit for its association with coactivators, Cdc20
and Cdh1 [38]. The co-activators are required along with
Apc10 for substrate recognition [38–40]. In common with
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Table 1: Fanconi Anemia genes and their products.
Gene MW (kDa) No. of amino acids Patient mutations
A 163 1455 60%
B 98 859 2%
C 63 558 13%
D1 384 3418 2%
D2 164 1451 3%
E 59 536 3%
F 42 374 3%
G 68 622 9%
I 150 1328 1%
J 141 1249 2%
L 42 375 0.2%
M 232 2048 0.2%
N 131 1186 0.6%
O 42 376 0.5%
P 200 1834 0.5%
FAAP24 24 215 —
FAAP100 100 881 —
MHF1 16 138 —
MHF2 10 81 —
Amino acids numbers were taken from the NCBI webserver, and patient mutational information was obtained from the Rockerfeller FA Mutations Database
and was calculated as a percentage of all individuals recorded in the database.
the CRLs, this ensemble allows flexibility and diversity in
substrate recognition.
By contrast, the CC has one subunit with E3 ligase
activity, FANCL [8] (Figure 2(c)), shown to be the only
subunit of the CC required for FANCD2 monoubiquiti-
nation in vitro [41]. FANCL is a RING E3 ligase [42],
which binds the E2 of the FA pathway, Ube2t [41, 43] in
a canonical fashion through its RING domain [43, 44].
Earlier in vitro and in vivowork indicated a FANCE-FANCD2
interaction [45] and a series of yeast and mammalian 2-
hybrid studies further support this interaction [46–48]. The
interaction of FANCD2 with a CC component prompted
the idea that FANCE may bring the substrates FANCD2 and
FANCI into close proximity of FANCL for their subsequent
monoubiquitination. As with other multisubunit E3 ligases,
this would leave FANCL as the “catalytic” subunit, indirectly
ubiquitinating substrates through its interaction with E2.
However, not only is FANCL suﬃcient in vitro for the
monoubiquitination event [41], but also has been shown
to interact directly with both FANCD2 and FANCI in vitro
[42, 44], and with FANCD2 in cells [49]. Althoughmutations
in other CC proteins result in a loss of the monoubiqui-
tination event, these more recent findings suggest FANCL
possesses all the requirements to be able to carry out the
monoubiquitination, unlike the multisubunit E3 ligases.
3. Protein-Protein Interactions
Required for CC Stability
Although the monoubiquitination event in vitro requires
only FANCL, it is clear from patient mutations that all
members of the CC are required in vivo. The reasons for
this are not clear, although numerous groups have shown
the CC proteins interact with one another and are required
to form a stable CC. Part of the challenge of gaining a
molecular understanding of the core complex lies in the lack
of obvious domain structures from primary sequences in any
of the proteins except FANCL and FANCM. This section will
describe the eﬀorts to understand the molecular biology of
the core complex to date.
3.1. FANCG-FANCA CC Interactions. FANCG and FANCA
have been shown to interact directly and indirectly through
yeast 2-hybrid, co-immunoprecipitations (co-IPs), cell-
based studies, and in vitro translational (IVT) work [25, 26,
46, 50–55] (Figure 3). Co-IPS and IVT studies suggested the
N-terminal 300 residues of FANCA bind FANCG [50, 51].
This region has been further narrowed down to the first
40 amino acids by a yeast 2-hybrid assay and the first 37
amino acids by a co-IP study [25, 46], with a requirement for
basic amino acids within this region for the interaction [25].
IVT studies indicate residues 18–29 of FANCA are suﬃcient
for a FANCG interaction, specifically Arginine 18, Arginine
19, and Leucine 25 [50]. Studies aimed at identifying the
regions of FANCG involved in a FANCA interaction are
more conflicting. Hussain et al. [55] reported via yeast 2-
hybrid analysis that the predicted TPR motifs 5 and 6 of
FANCG, which reside in the C-terminal 170 residues, were
required for the interaction. Consistent with this finding,
IVT assays also revealed two FANCA binding regions in
the C-terminal 222 residues of FANCG: one encompassing
the same predicted TPR motifs 5 and 6, and the second
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Figure 2: Models of multisubunit E3 ligases. (a) A model of the proteins that make a Cullin-RING E3 ligase (CRL). The Cullin protein
(lilac) acts as scaﬀold and binds the RING domain (cyan) required for E2 binding and the substrate binding proteins (pink, red, blue) via an
adaptor. The variety of substrate binding proteins allows the CRLs flexibility in binding a range of substrates. (b) A model of the Anaphase
Promoting Complex (APC). The catalytic core consists of a Cullin repeat protein Apc2 (lilac), which acts a scaﬀold for the RING protein,
Apc11 (cyan), and the substrate binding protein Apc10 (red). For substrate recognition the APC also binds coactivators (dark blue). The
APC also consists of a TPR subcomplex (green) and a platform (yellow) which orient the catalytic unit and aid binding to the co-activators.
The range of subunits allows a variety of substrates to be recognised. (c) Amodel of the Fanconi Anemia Core Complex. The catalytic activity
resides in one protein FANCL (mauve). The rest of the CC proteins are coloured blue, with light blue representing proteins associated with
the CC.
residing in the last 37 residues of FANCG [50]. However,
in contrast, a yeast 2-hybrid study found the C-terminal 142
amino acids of FANCG to be dispensable for interaction with
FANCA [46]. To add to the complexity, other studies report
a requirement for additional regions throughout FANCG for
a FANCA interaction [52, 54, 56] with Wilson et al.’s [56] in
vivo study indicating several regions, TPR motifs 1, 2, 5, and
6 throughout FANCG are required.
FANCG null lymphoblasts have a defect in FANCA
nuclear accumulation, which can be rescued by the addition
of FANCG, suggesting that FANCG plays a role in the
subcellular localization of FANCA [26]. Indeed, the FANCG
interaction with FANCA appears to promote FANCA nuclear
accumulation [26]. However, a thorough analysis of multiple
FANCA patient mutations suggests that FANCG binds
FANCA even when the nuclear localisation of FANCA
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Figure 3: A model of CC interactions. (a) Models of the CC proteins that directly interact with one another, represented by black lines. Yeast
and mammalian 2-hybrid and in vitro and translational studies have shown these interactions. (b) Associated CC interactions as shown by
mammalian and yeast 3-hybrid experiments. (c) A model of how all the CC proteins interact to from the full CC, the requirement for the
monoubiquitination event.
is lost [57]. The FANCA extreme N-terminus contains a
nuclear localisation signal (NLS) [25, 58]. FANCA patient
mutations are varied and account for 60% of all FA cases
(Table 1) and predominantly result in loss of FANCA nuclear
accumulation [57]. It appears likely that a combination of the
NLS on FANCA and FANCG-binding stabilise, and supports
the nuclear subcellular localisation of the core complex.
These studies all indicate a likely physical interaction
between FANCG, and FANCA, but themolecular details have
yet to be fully resolved.
3.2. FANCF CC Interactions. FANCF has been implicated in
the physical stability of the majority of other CC proteins,
FANCC, FANCE, FANCG and FANCA by several groups
[27, 28, 59, 60]. X-ray crystallographic analysis of a C-
terminal portion of FANCF (residues 156–357) revealed an
architecture of helical repeats [60], similar to those found
in scaﬀolding proteins. Structure-based mutations were then
generated for use in mammalian co-IP assays. Using both
point mutations L209R and F251R and a hydrophobic
patch mutation Y287A/L289A/F339A/V341A/L344A, Kowal
and coworkers [60] verified and provided the molecular
details of the FANCF associations with FANCA and FANCC
reported from earlier co-IP studies [27]. In addition, a
further association with FANCE was identified [60]. In
contrast to the structure-based analysis, Le´veille´ et al. [59]
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use coimmunoprecipitation from cultured lymphoblasts and
report the requirement of the last 31 amino acids (343–
374) of FANCF for a FANCG and FANCA interaction and
additionally report that the first 15 N-terminal amino acids
are required for a FANCE and FANCC interaction.
Yeast and mammalian 3-hybrids revealed that a FANCC-
FANCE interaction was required for a direct interaction with
FANCF [59, 61]. In accordance with their co-IP studies,
Le´veille´ et al. [59] show residues Leu5/Leu8/Leu15 are
required for a FANCC-FANCE interaction in their mam-
malian 3-hybrid assay and report two additional regions,
Arg10/Phe11/Arg47/Phe48 and Ser18/Ser19/Thr20/Thr21,
also required for this interaction [59]. Whilst these findings
are not necessarily incompatible, the molecular details of
the interactions between FANCF and FANCG, FANCA and
FANCE are still unresolved.
The FANCA-FANCF interaction is mediated by FANCG,
from yeast 3-hybrid analyses [46]; conversely co-IP stud-
ies indicate a FANCA-FANCG interaction is stabilized by
FANCF [27]. Both these observations are supported by
yeast 2-hybrid experiments that show a direct interaction of
FANCG with FANCF [28, 46, 55, 59]. Gordon and Buchwald
[46] show that this interaction resides in the last 131 C-
terminal residues of FANCF, and Le´veille´ et al. [59] narrow
this down to the last 40 amino acids in their yeast 2-hybrid
assay. Several groups have attempted to map the region of
FANCG responsible for a FANCF interaction by yeast 2-
hybrid analysis, all of which conclude that several sites are
required throughout the full amino acid sequence of FANCG
[46, 52, 55].
Importantly, structure-guided mutagenesis of FANCF
increased MMC sensitivity, thereby directly showing FANCF
interactions are critical [60]. Although there are conflicting
results regarding FANCF associations with other CC mem-
bers, numerous studies all support the role for FANCF in
coordinating and stabilizing other CC proteins, as seen for
FANCG.
3.3. FANCE-FANCC CC Interactions. A FANCC-FANCE
interaction and their association with other members of the
CC have been documented by yeast and mammalian 2- and
3-hybrid assays, IVT studies and co-IPs [28, 45–47, 59, 62].
The central part of FANCE, residues 149–371, is required
for the FANCC interaction as seen by yeast and mammalian
2-hybrid experiments [46, 47]. However, the corresponding
regions of FANCC required for the interaction were not
determined. More recent studies employing mammalian and
yeast 3-hybrid assays indicate the importance of a FANCC-
FANCE interaction to facilitate a direct interaction with
FANCF [59, 61]. This interaction of FANCE with FANCF
explains early co-IP findings of FANCEs associations with
FANCA, FANCG, and FANCF [45, 62], as FANCF has
been shown to directly interact with FANCG, and FANCG
directly interacts with FANCA, indicating a possible indirect
association of these proteins.
3.4. FANCL-FANCB CC Interactions. Research has indicated
FANCL is required to form a stable CC using co-IP
experiments and size exclusion chromatography [63, 64].
Alpi et al. [64] show that in a wild-type chicken DT40 lym-
phoblastoid cell line, a complex of 1.5MDa pulled out using
a Tandem-aﬃnity tagged FANCC exists. In corresponding
FANCL-null cells, this complex is both less abundant and a
lower molecular weight. However, the 1.5MDa complex is
established again upon expressing FANCL [64]. Consistent
with these data, co-IPs in FANCL-null cells show a disruption
of the interactions of FA CC proteins [63]. In the same
study, a mammalian 2-hybrid assay indicates that FANCL
forms a direct interaction with the CC via FANCB [63]
(Figure 3). Medhurst et al. [63] also suggest that FANCL-
FANCA interactions are mediated through FANCB and that
FANCG is required to stabilize FANCA in this interaction.
Additionally Alpi et al. [64] demonstrate that the stabilizing
role of FANCL for the CC is independent from its E3 ligase
activity, as point mutations that disrupt the RING domain
and inhibit the monoubiquitination activity can still form
a stable CC when introduced into the FANCL-null cell
line. It is clear that FANCL is an important member of
the CC for stability; however, molecular details, including
the stoichiometry and domain requirements of how FANCL
interacts with the CC are still lacking.
The intricacy of, these CC protein-protein interactions
is further complicated by the findings that a FANCA-
FANCG interaction is required in stabilizing a FANCC-
FANCA interaction and the need for FANCE to support the
FANCA-FANCC interaction [25, 62].
The extensive research described here reflects a complex
network of interactions between the CC proteins (summa-
rized in Figure 3), all of which seem to be a requirement for
a fully stable CC.
4. Subcomplexes, Stoichiometry, and
Assembly of the CC
As discussed above FANCA has an NLS and monoubiqui-
tinated FANCD2 locates at nuclear foci on chromatin as
seen by fluorescent microscopy and co-IP studies [7, 65, 66].
However, FANCD2 has also been located in the cytoplasm
[67–70] as have several of the CC components [8, 27, 51, 71].
Such findings give rise to the possibility that subcomplexes of
the CC exist and localize in diﬀerent cellular regions.
Meetei et al. [72] reported diﬀerent ratios of CC proteins
observed in their co-IPs studies suggesting the idea of
subcomplexes, although this could also reflect diﬀerent
stoichiometry of the CC proteins. An analysis of CC proteins
isolated from the cytoplasm at diﬀerent stages of the cell
cycle revealed diﬀerent molecular weight protein complexes
by size exclusion chromatography [73]. A complex that
consists of a single copy of each FA protein of the CC
would give an approximate 737 kDa complex, which would
increase to 861 kDa if FAAP24 and FAAP100 were included.
Thomashevski et al. [73] report a 600 kDa cytoplasmic
complex that increases to a 750 kDa complex during mitosis,
supporting the idea of subcomplexes. One study documents
such a subcomplex: FANCL-FANCB-FAAP100, which was
tandem aﬃnity purified from HeLa cell extracts [29].
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Ling et al. [29] also suggest this subcomplex has a stoi-
chiometric ratio of 1 : 1 : 1 in both cytoplasmic and nuclear
extracts, with a more prominent association with FANCA
in the nucleus. They speculate FANCA along with FANCM
may localize the FANCL-FANCB-FAAP100 subcomplex to
the nucleus [29]. Medhurst et al. [63] also support the idea
of subcomplexes as they reveal from immunoprecipitation
experiments of FANCG that FANCA and FANCL are copre-
cipitated independently of FANCE, FANCC, and FANCF.
Studies identifying the localization of individual CC proteins
by fluorescence microscopy in cells indicate FANCF and
FANCE, which give a joint molecular weight of 101 kDa, are
predominantly located in the nucleus, independently of any
other CC proteins [27, 45, 47, 62]. FANCEs absence from
any cytoplasmic complex described by Thomashevski et al.
[73] further supports FANCEs localization in the nucleus.
As a full complement of CC proteins is required for the
monoubiquitination event, the observations of cytoplasmic
subcomplexes and nuclear localization of certain CC proteins
prompt the idea of the assembly of the full CC in the nucleus.
The study by Thomashevski et al. [73] supports the idea
of the full CC residing in the nucleus, as they report a
large nuclear complex of 2MDa and a 1MDa chromatin
associated complex, both containing CC proteins. As stated
above, a CC consisting of one copy of each protein would
give an approximate molecular weight of 861 kDa (including
FAAP24 and FAAP100). Their reports suggest the nuclear
and chromatin complexes may contain multiple copies
of CC proteins and indicate the associations of the CC
proteins and their stoichiometry diﬀer between the two
nuclear and chromatin complexes. Additionally components
of these large nuclear complexes are likely to include other
nuclear proteins, such as the BLM proteins and MHF1
and MHF2. Meetei et al. [72] report a 1.5–2MDa complex
when immunoprecipitating the BLM complex and found
this complex to contain CC proteins. FANCM has since
been appointed the CC protein interacting with the BLM
proteins, as shown by co-IPs, in vitro translational work
and fluorescence microscopy [74]. Likewise, Yan et al. [35]
report a 1MDa complex containing CC proteins and the
FANCM-associated histone-fold proteins 1 and 2 (MHF1
and MHF2). Elucidating the existence of subcomplexes and
a large nuclear CC certainly complicates the understanding
of the CC. However, these studies highlight the importance
of understanding both the assembly and stoichiometry of the
CC and its subcomplexes. Whether there are additional roles
for the subcomplexes is not yet understood.
5. FANCM: A Member of the CC?
FANCM is considered a member of the CC, as it co-
immunoprecipitates with other CC proteins and the loss
of FANCM results in a loss of DNA damaged induced
monoubiquitination and nuclear localization of other CC
proteins [3, 30, 75, 76]. Indeed FANCM is thought to
promote DNA damage-induced monoubiquitination of
FANCD2 by recruitment of the CC via FANCF through its
MM1 region [74]. Deans and West [74] also show deletions
of regions throughout FANCF reduce an interaction with
FANCM and deletion of FANCF residues 1–158 completely
disrupt this interaction. The C-terminal end of FANCM
associates with FAAP24 and both are thought to stabilize
one another, [30, 76]. Ciccia et al. [30] also suggest the
stability of FANCM-FAAP24 complex may be dependent on
FANCB. However, Kim et al. [77] suggest FANCM recruits
the CC proteins to chromatin and is not required for a
stable CC. The histone-fold proteins MHF1 and MHF2 form
another complex with FANCM [78] and are suggested to
aid with the remodelling of DNA, as seen by co-IPs, size
exclusion chromatography and DNA binding assays [34, 35].
Although the loss of MHF1 and MHF2 results in a loss
of FANCD2 DNA damage inducible monoubiquitination,
in agreement with Kim et al. [77], Yan et al. [35] report
more than 70% of this complex is independent from the CC.
A recent structural analysis reveals that MHF1 and MHF2
form a heterotetrameric complex and that disrupting the
heterotetrameric interfaces results in an increased sensitivity
to DNA damaging agents as seen by methyl methanesul-
fonate (MMS) treatment sensitivity assays in yeast [78]. A
loss of FANCM has shown a loss of DNA damage inducible
monoubiquitination of FANCD2 and many groups have
suggested its role as a member of the CC; however, evidence
is directing its role upstream of the CC suggesting it acts as
a platform to recruit proteins to DNA. Additional evidence
shows the FANCM-FAAP24 subcomplex has also been asso-
ciated with interactions of the BLM complex [30, 74]. The
role of FANCM in both Bloom syndrome and FA explains the
similarities of the BLM and FA patients’ high predisposition
to cancer. Additionally the FANCM-FAAP24 subcomplex has
also been implicated in ataxia telangiectasia and Rad3-related
protein (ATR), a protein kinase associated with cell cycle
arrest and checkpoint signalling independently from the rest
of the CC proteins, through binding HCLK2 [79].
6. Discussion
The FA pathway has rapidly expanded over the last 15
years to a current count of 15 proteins. The number of FA
proteins reflects the complicated nature of understanding
the FA pathway, particularly the CC, which consists of over
half of the FA proteins. Ascertaining functions for the FA
proteins have been exceptionally challenging due to the
lack of information divulged from the primary amino acid
sequences. Extensive eﬀorts have beenmade by researchers to
define the roles of the individual CC proteins within the CC
and to understand the need for such a large CC. However,
there are still many remaining questions.
(1) How does the CC support FANCLs E3 ligase activity?
Is there a requirement for other CC proteins to
localize FANCL to the nucleus? Or do the other
CC proteins act as a structural scaﬀold for the
monoubiquitination event?
(2) Do the subcomplexes come together to form a
full CC? If so how and where does the assembly
take place? And are there independent roles for the
subcomplexes?
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(3) What are the molecular and stoichiometric details
of the CC? The requirement for all CC proteins for
the monoubiquitination event is clear from patients
with defects in the CC. Therefore, understanding
the molecular details of the protein interactions
that occur in the CC is key, because therapeutics
could be designed to restore or diminish these
interactions and furthermore tailored to the diﬀerent
FA complementation groups. The combination of
biochemical, biophysical, clinical, and cell work will
in time answer these questions.
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